Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth
Almirall's unique dedication to medical dermatology and innovation - combined with its commercial excellence - fuel an era of sustained double-digit growth (net sales CAGR 2023-2030) and profitability enabling the company to reach more patients with relevant and impactful productsGrowth of Almirall’s psoriasis and atopic dermatitis franchises is anticipated to lead to over 800 million in annual peak sales in biologics, driven by Ebglyss® and Ilumetri®Strategic investments in commercial excellence, R&D and science leadership provide the basis for realising Almirall’s market potential as European leader in medical dermatology
Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, commercial excellence, and its continued investment in R&D to innovate and advance science.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113044812/en/

Almirall HQ in Barcelona (Photo: Business Wire)
Almirall combines the strengthening of its growth drivers, particularly the biologics products, with the continued growth of its broad portfolio of medical dermatology solutions, including Klisyri®, Wynzora®, and Seysara®. Almirall’s commercial excellence has been demonstrated by the successful launches of biologics across key markets in Europe. The success of the key growth drivers of Almirall has enabled the company to adjust the anticipated peak sales figures for the biologics portfolio to more than 800MM Eur annually comprising of expected peak sales for Ebglyss® of above 450MM Eur, and Ilumetri® of above 300MM Eur.
This development sees Almirall at a turning point entering an era of sustained double-digit growth (net sales CAGR 2023-2030) that is enabled by the previous investments into commercial capabilities for the launch of breakthrough assets, into capabilities, expertise, and infrastructure. This growth will mainly be driven by biologics which are well placed to take significant market share in these segments that show sustained overall increase and a transition of more patients to advanced treatment options.
Importantly, Almirall will continue to invest in its leading R&D capabilities in medical dermatology driving science leadership and enabling the company to develop disruptive and innovative products that build sustainable future growth as a leader in medical dermatology.
Medical Dermatology: Significant unmet needs and growth potential
Medical dermatology continues to be a pharmaceutical sector with significant unmet needs based on the severe patient impact of a wide range of dermatological diseases, the many uncontrolled patients with chronic diseases, increasing numbers of diagnoses, and the transition of more patients to advanced treatments. Almirall has significant potential for growth in this sector due to its dedication to medical dermatology, commercial capabilities, close collaboration with the medical community, and its proven end-to-end capabilities across the entire value chain. This enables Almirall to give patients and the medical community access to innovative and relevant solutions and contribute to improving their lives.
The company has continuously invested around 12% of its Net Sales in R&D over many years, laying the foundation for continued growth and acceleration in the future and creating and advancing a strong pipeline in key areas, both in clinical and preclinical stages.
Almirall has a broad range of collaborations that help to advance science and enable the development of disruptive new treatments across different modalities. The company continues to focus on building collaborations with partners that have new platforms and technologies to further develop its innovative pipeline. We access the latest available technologies, including small molecules, biologics, and other modalities such as mRNA, for example through the multi-target alliance with etherna to discover and develop innovative and disruptive mRNA / LNP therapies.
"2025 is a turning point for Almirall as we are entering an era of sustained double-digit growth of our net sales CAGR to 2030, and increased EBITDA margins to around 25% by 2028. We are dedicated to improving patients' lives and advancing medical dermatology through our leading research and development initiatives and giving patients access to novel and impactful treatment options – now and in the future," stated Carlos Gallardo, CEO and President of Almirall. "We continue with our sustained investment in R&D to lead science, innovation and excellence in medical dermatology. Almirall is a partner of choice for dermatologists and together we will impact more patients' lives in line with our company’s growth.”
“Our robust financial situation enables us to invest in long-term growth opportunities which are aligned with our business strategy and ambition as leaders in medical dermatology. By building on our strong portfolio, and making strategic investments, we are well-positioned to meet our ambitious objectives and generate long-term value for shareholders. Our primary advantage lies in our collaborative mindset, agility, and ability to seize opportunities swiftly. This approach also allows us to distribute development costs efficiently,” stated Mike McClelllan, Almirall's CFO.
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit almirall.com
Disclaimer
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113044812/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody16.9.2025 02:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previously signed research collaboration and option agreement to discover and advance antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery engine. The antibody was generated using Biocytogen’s proprietary RenMice® platform and features high affinity, low immunogenicity, and favorable developability. Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies based on this antibody, aiming to addr
CSC Digital Brand Services Announces Integration into CrowdStrike Falcon Adversary Intelligence’s Recon to Accelerate Detection and Enforcement Against Malicious Domains15.9.2025 23:27:00 CEST | Press release
CSC, the world’s leading enterprise-class domain registrar and online brand protection provider, announced today at Fal.Con 2025 a new integration of CSC’s domain security offerings with the CrowdStrike Falcon® cybersecurity platform. The integration with Recon, a core capability within Falcon Adversary Intelligence, enables organizations to accelerate the detection and takedown of malicious domains, reducing exposure to phishing, fraud, and brand abuse. As cybercrime reaches unprecedented levels, adversaries are increasingly exploiting digital assets, brands, and domain name system (DNS) infrastructure. Traditional defenses often overlook domain portfolios, leaving organizations vulnerable to spoofing, impersonation, and account takeovers. CSC and CrowdStrike are uniting to close this gap with a comprehensive solution that integrates advanced threat intelligence, rapid detection, and global enforcement. Through this integration, clients can: Leverage the Recon capability in Falcon Adv
Celonis Debuts at No. 3 on the 2025 Fortune Future 5015.9.2025 22:58:00 CEST | Press release
Celonis, a global leader in Process Mining, today announced it has been named to No. 3 on the 2025 Fortune Future 50 list, recognized among the world’s most promising companies poised for long-term growth. This marks the company’s first appearance on the list alongside a prestigious group of global innovators, and underscores its leadership in enabling successful AI and business transformation through Process Intelligence. Published annually in collaboration with the Boston Consulting Group, the Fortune Future 50 evaluates more than 2,000 public companies to identify those best positioned for sustained growth based on a proprietary system analyzing market potential, innovation, strategy, and investment in the future. “Being named to the Fortune Future 50 is powerful validation of the mission we’ve been on since day one - to make processes work for people, companies and the planet,” said Alex Rinke, co-CEO and co-founder of Celonis. “This is truly just the beginning of seeing how Proces
ElevenLabs-Powered Chroma Awards Opens Call For Submissions, With November 3 Deadline15.9.2025 15:00:00 CEST | Press release
Creator-Led Global AI Film, Music Video, and Games CompetitionUniting the Global AI Creative Community Chroma Awards, a groundbreaking AI Film, Music Video, and Games competition organized by ElevenLabs, the leading AI audio research and product company, announced today that submissions are open for its inaugural competition, with a November 3 deadline. Competition participants can access free trials of AI tools provided by sponsors starting today at https://pack.chromaawards.com/. The Chroma Awards was established with the mission to educate, empower, and spotlight the next generation of artists and showcase how AI can empower human creativity. The competition is organized by ElevenLabs and presented by Google Cloud, Freepik, fal, Dreamina AI, and CapCut. “Through this initiative we hope to unite creators, communities, and companies across the world to bring emerging technology and creative talent together in dialogue,” said Matty Shimura, Chroma Awards. “We’re incredibly grateful to
33 Innovators Join Morgan Stanley Inclusive & Sustainable Ventures Cohort15.9.2025 14:08:00 CEST | Press release
Accelerator’s expanded focus includes sustainable solutions and support for nonprofits 2025 cohort comprised of 33 early-stage innovators from the Americas and EMEA Five-month program to provide founders with $250,000 (£250,000), as well as mentorship and growth resources Morgan Stanley (NYSE: MS) today announced the global cohort of its Inclusive & Sustainable Ventures (MSISV). With founders from the Americas and Europe, the Middle East and Africa (EMEA), the 2025 MSISV cohort will support 29 startups in its Lab and four emerging nonprofits in its Collaborative, two in-house accelerators that will run over the next five months. Selected from thousands of applications, the 33 organizations will engage in a tailored entrepreneurship curriculum and receive mentorship and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners. The firm will invest $250,000 (£250,000 in EMEA) in each startup and provide each nonprofit with a $250,000 grant. “Morgan Stan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom